Metsera (NASDAQ:MTSR) Shares Down 5.2% - Here's Why

Metsera, Inc. (NASDAQ:MTSR - Get Free Report) shares fell 5.2% on Friday . The stock traded as low as $32.44 and last traded at $32.79. 210,943 shares were traded during trading, a decline of 77% from the average session volume of 902,864 shares. The stock had previously closed at $34.58.

Analyst Ratings Changes

Several analysts have recently issued reports on the stock. Cantor Fitzgerald assumed coverage on shares of Metsera in a research note on Tuesday, February 25th. They issued an "overweight" rating for the company. Evercore ISI began coverage on shares of Metsera in a research report on Tuesday, February 25th. They set an "outperform" rating for the company. Bank of America assumed coverage on shares of Metsera in a research report on Tuesday, February 25th. They set a "buy" rating and a $38.00 target price for the company. Finally, Guggenheim increased their price target on shares of Metsera from $56.00 to $62.00 and gave the stock a "buy" rating in a report on Tuesday, June 10th.

Metsera Trading Down 8.5%

The firm has a fifty day moving average price of $24.64.

Metsera (NASDAQ:MTSR - Get Free Report) last announced its earnings results on Monday, May 12th. The company reported ($1.03) earnings per share for the quarter.

Institutional Investors Weigh In On Metsera

Institutional investors and hedge funds have recently bought and sold shares of the stock. Strs Ohio purchased a new stake in Metsera in the first quarter valued at approximately $76,000. New York State Common Retirement Fund purchased a new stake in Metsera in the first quarter valued at approximately $131,000. Corebridge Financial Inc. purchased a new stake in Metsera in the first quarter valued at approximately $206,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new stake in Metsera in the first quarter valued at approximately $248,000. Finally, MetLife Investment Management LLC purchased a new stake in Metsera in the first quarter valued at approximately $254,000.

About Metsera

Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.